COPD
Conditions
Interventions
Case series:tiotropium + olodaterol fixed-dose combination (5 µg / 5 µg)
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Male
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. All patients must sign an informed consent consistent with ICH-GCP guidelines and local legislations prior to any study-related procedures, which includes medication washout and restrictions; 2. All patients must have a diagnosis of COPD [P11-05865] and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a post-bronchodilator FEV1 30% of predicted normal and <80% of predicted normal (ECSC, [R94-1408]; and a postbronchodilator FEV1/ FVC<70% at Visit 1 (See Appendix 10.4 for ECSC predicted normal equations). 3. Male or female patients, 40 years of age or older. 4. Patients must be current or ex-smokers with a smoking history of more than 10 pack years. (See Appendix 10.4 for calculation). Patients who have never smoked cigarettes must be excluded. 5. Patients must be able to ? perform technically acceptable pulmonary function tests, ? maintain medication worksheet records during the study period, ? perform all other assessments as required in the protocol. 6. Patients must be able to inhale medication in a competent manner from the RESPIMAT inhaler (See Appendix 10.2) and from a metered dose inhaler (MDI). 7. Male or female patients. Women of childbearing potential* must be ready and able to use highly effective methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
Exclusion criteria
Exclusion criteria: 1. Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patients ability to participate in the study. 2. Patients with a, in the opinion of the investigator, clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT > 2 x ULN, SGPT > 2 x ULN, bilirubin > 2 x ULN or creatinine > 2 x ULN will be excluded regardless of clinical condition (a repeat laboratory evaluation will not be conducted in these patients). 3. Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count =600/mm3, source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition. Patients with any of the following conditions: 4. A diagnosis of thyrotoxicosis (due to the known class side effect profile of ?2-agonists). 5. A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ?2-agonists) 6. A history of myocardial infarction within 1 year of screening visit (Visit 1). 7. Unstable or life-threatening cardiac arrhythmia. 8. Hospitalization for heart failure within the past year. 9. Known active tuberculosis. 10. A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed). 11. A history of life-threatening pulmonary obstruction. 12. A history of cystic fibrosis. 13. Clinically evident bronchiectasis. 14. A history of significant alcohol or drug abuse. 15. Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1). 16. Patients being treated with oral or patch ß-adrenergics. 17. Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day. 18. Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigators opinion will be unable to abstain from the use of oxygen therapy during clinic visits. 19. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program. 20. Patients who have taken an investigational drug within one month or six half lives or (in case the investigational drug (sub) class is listed in Table 4.2.2.1:1) within the wash out period specified in Table 4.2.2.1:1 (whichever is greater) prior to screening visit (Visit 1). 21. Patients with known hypersensitivity to ß-adrenergics and/or anticholinergic drugs, BAC, EDTA or any other component of the RESPIMAT inhalation solution. 22. Women who are pregnant, nursing, or who plan to become pregnant while in the trial 23. Women of childbearing potential not using two highly effective methods of birth control*. Female patients will be considered to be of childbearing potential unless surgically steril
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma drug concentration; | — |
Countries
China
Contacts
Public ContactZhu Luo
West China Hospital, Sichuan University
Outcome results
None listed